This trial will compare LNP023 to rituximab to see if LNP023 is more effective and safe in treating MN.
- Membranous Glomerulonephritis
1 Primary · 11 Secondary · Reporting Duration: Day 29 and Day 113 (pre-dose and 0.25 hours, 0.5 hours, 1 hour 2 hours, 4 hours and 6 hours post dose)
Side Effects for
2 Treatment Groups
1 of 2
1 of 2
37 Total Participants · 2 Treatment Groups
Primary Treatment: LNP023 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the approximate number of participants engaged in this research project?
"Affirmative. The clinicaltrials.gov listings indicate that recruitment for this research has started and is ongoing, with the original posting dating back to November 23rd 2019. There are currently 4 sites searching for a total of 52 participants." - Anonymous Online Contributor
Are there any openings in this medical investigation that would accommodate a new participant?
"Clinicaltrials.gov verifies that this medical experiment is actively engaging participants. It was initially posted on the 23rd of November 2019 and the most recent iteration occurred on 18th of November 2022." - Anonymous Online Contributor
In which geographical areas is the trial being conducted?
"This clinical trial is presently being conducted in 4 different cities: Cleveland, New York, Temple and more. It would be beneficial to choose the closest medical centre for you to minimize your commuting needs should you participate." - Anonymous Online Contributor
Could you provide a summary of the research done on LNP023 thus far?
"The initial trials of LNP023 took place in 1993 at the National Institutes of Health Clinical Center, 9000 Rockville Pike. 809 studies have been conducted since then; presently 415 live experiments are taking place across the nation with a significant percentage based out of Cleveland, Ohio." - Anonymous Online Contributor
What health conditions is LNP023 commonly used to treat?
"LNP023 is an efficacious therapy for the treatment of diffuse large b-cell lymphoma, in addition to conditions such as polyangium and pemphigus vulgaris." - Anonymous Online Contributor
Has the FDA approved LNP023 for therapeutic use?
"The efficacy of LNP023 is yet to be proven, thus it scored a 2 on our team's safety scale. This Phase 2 trial has yielded some reassuring data regarding the drug's security profile." - Anonymous Online Contributor